Xiaofeng Lan
Data updated
Papers
Trials
Research Footprint
Xiaofeng Lan appears in 7 tracked papers (2021–2024), most studied alongside Ketamine, Esketamine and Placebo, across Depressive Disorders, Suicidality and Major Depressive Disorder (MDD).
Most-cited paper: Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial (51 citations).
Frequent co-authors: Yanling Zhou, Chengyu Wang and Yuping Ning.
Background & Research
Xiaofeng Lan appears as an author on multiple clinical studies of repeated intravenous ketamine and esketamine for major depressive disorder, suicidal ideation, and cognition. The publications associate Lan with the Affiliated Brain Hospital of Guangzhou Medical University in Guangzhou, China, and related psychiatry/neuroimaging work on treatment response and suicide outcomes.
Key Impact
Clinical ketamine/esketamine researcher whose work links repeated ketamine treatment with cognition, suicidality, and neuroimaging biomarkers in mood disorders.
Collaboration Network
5 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Xiaofeng Lan is associated with.